The development of dendritic cell vaccine-based immunotherapies for glioblastoma

[1]  D. Mitchell,et al.  Gene-modified dendritic cell vaccines for cancer. , 2016, Cytotherapy.

[2]  S. Nierkens,et al.  Migration of dendritic cells to the lymph nodes and its enhancement to drive anti-tumor responses. , 2016, Critical reviews in oncology/hematology.

[3]  Christopher A. Miller,et al.  Endogenous Neoantigen-Specific CD8 T Cells Identified in Two Glioblastoma Models Using a Cancer Immunogenomics Approach , 2016, Cancer Immunology Research.

[4]  Atique U. Ahmed,et al.  Intranasal Oncolytic Virotherapy with CXCR4-Enhanced Stem Cells Extends Survival in Mouse Model of Glioma , 2016, Stem cell reports.

[5]  T. Ashizawa,et al.  Antitumor Effect of Programmed Death-1 (PD-1) Blockade in Humanized the NOG-MHC Double Knockout Mouse , 2016, Clinical Cancer Research.

[6]  G. Rall,et al.  Get It through Your Thick Head: Emerging Principles in Neuroimmunology and Neurovirology Redefine Central Nervous System "Immune Privilege". , 2016, ACS chemical neuroscience.

[7]  G. Dunn,et al.  Principles of immunology and its nuances in the central nervous system. , 2015, Neuro-oncology.

[8]  M. Weller,et al.  Immunosuppressive mechanisms in glioblastoma. , 2015, Neuro-oncology.

[9]  M. Gilbert,et al.  Immunotherapy for neuro-oncology: the critical rationale for combinatorial therapy. , 2015, Neuro-oncology.

[10]  T. Chan,et al.  Cancer Neoantigens and Applications for Immunotherapy , 2015, Clinical Cancer Research.

[11]  H. Goossens,et al.  Dendritic Cells as Pharmacological Tools for Cancer Immunotherapy , 2015, Pharmacological Reviews.

[12]  Maxim N. Artyomov,et al.  Tumor neoantigens: building a framework for personalized cancer immunotherapy. , 2015, The Journal of clinical investigation.

[13]  R. Pabst.  Mucosal vaccination by the intranasal route. Nose-associated lymphoid tissue (NALT)-Structure, function and species differences. , 2015, Vaccine.

[14]  K. Hongo,et al.  Dendritic cell-based immunotherapy targeting Wilms' tumor 1 in patients with recurrent malignant glioma. , 2015, Journal of neurosurgery.

[15]  N. Bertho,et al.  Investigating Evolutionary Conservation of Dendritic Cell Subset Identity and Functions , 2015, Front. Immunol..

[16]  Timothy J Keyes,et al.  Structural and functional features of central nervous system lymphatics , 2015, Nature.

[17]  J. Lunceford,et al.  Pembrolizumab for the treatment of non-small-cell lung cancer. , 2015, The New England journal of medicine.

[18]  R. Motzer,et al.  Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  T. Schumacher,et al.  Neoantigens in cancer immunotherapy , 2015, Science.

[20]  M. Gilbert,et al.  Treating recurrent glioblastoma: an update. , 2015, CNS oncology.

[21]  T. Kleine.  Cellular immune surveillance of central nervous system bypasses blood–brain barrier and blood–cerebrospinal–fluid barrier: Revealed with the New Marburg cerebrospinal–fluid model in healthy humans , 2015, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

[22]  R. McLendon,et al.  Tetanus toxoid and CCL3 improve DC vaccines in mice and glioblastoma patients , 2015, Nature.

[23]  H. Fine.  New Strategies in Glioblastoma: Exploiting the New Biology , 2015, Clinical Cancer Research.

[24]  C. Reis e Sousa,et al.  Defining dendritic cells. , 2015, Current opinion in immunology.

[25]  D. Bigner,et al.  Novel role of hematopoietic stem cells in immunologic rejection of malignant gliomas , 2015, Oncoimmunology.

[26]  D. Schadendorf,et al.  Nivolumab in previously untreated melanoma without BRAF mutation. , 2015, The New England journal of medicine.

[27]  J. Wolchok,et al.  Immune Checkpoint Blockade in Cancer Therapy. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  P. Wen,et al.  Glioma in 2014: Unravelling tumour heterogeneity—implications for therapy , 2015, Nature Reviews Clinical Oncology.

[29]  J. Sampson,et al.  Enhancing dendritic cell-based vaccination for highly aggressive glioblastoma , 2015, Expert opinion on biological therapy.

[30]  A. Heimberger,et al.  Immunotherapy for Primary Brain Tumors: No Longer a Matter of Privilege , 2014, Clinical Cancer Research.

[31]  A. Friedman,et al.  Severe Adverse Immunologic Reaction in a Patient with Glioblastoma Receiving Autologous Dendritic Cell Vaccines Combined with GM-CSF and Dose-Intensified Temozolomide , 2014, Cancer Immunology Research.

[32]  J. Barnholtz-Sloan,et al.  Glioblastoma survival: has it improved? Evidence from population-based studies. , 2014, Current opinion in neurology.

[33]  Hongyang Zhao,et al.  Dendritic Cell-Based Vaccine for the Treatment of Malignant Glioma: A Systematic Review , 2014, Cancer investigation.

[34]  C. Kurts,et al.  Dendritic cell-targeted vaccines — hope or hype? , 2014, Nature Reviews Immunology.

[35]  K. Aldape,et al.  Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial. , 2014, The Lancet. Oncology.

[36]  Shawn M. Gillespie,et al.  Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma , 2014, Science.

[37]  L. Liau,et al.  Cytokine responsiveness of CD8+ T cells is a reproducible biomarker for the clinical efficacy of dendritic cell vaccination in glioblastoma patients , 2014, Journal of Immunotherapy for Cancer.

[38]  C. James,et al.  Immunocompetent murine models for the study of glioblastoma immunotherapy , 2014, Journal of Translational Medicine.

[39]  K. Aldape,et al.  A randomized trial of bevacizumab for newly diagnosed glioblastoma. , 2014, The New England journal of medicine.

[40]  K. Hoang-Xuan,et al.  Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. , 2014, The New England journal of medicine.

[41]  Walter J Curran,et al.  Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  Antoni Ribas,et al.  Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. , 2013, The New England journal of medicine.

[43]  S. Aamdal,et al.  Therapeutic vaccination against autologous cancer stem cells with mRNA-transfected dendritic cells in patients with glioblastoma , 2013, Cancer Immunology, Immunotherapy.

[44]  N. Senzer,et al.  OPTiM: A randomized phase III trial of talimogene laherparepvec (T-VEC) versus subcutaneous (SC) granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment (tx) of unresected stage IIIB/C and IV melanoma. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  E. Parati,et al.  The natural killer cell response and tumor debulking are associated with prolonged survival in recurrent glioblastoma patients receiving dendritic cells loaded with autologous tumor lysates , 2013, Oncoimmunology.

[46]  A. Salazar,et al.  Vaccine Injection Site Matters: Qualitative and Quantitative Defects in CD8 T Cells Primed as a Function of Proximity to the Tumor in a Murine Glioma Model , 2013, The Journal of Immunology.

[47]  T. Ashizawa,et al.  α-type-1 polarized dendritic cell-based vaccination in recurrent high-grade glioma: a phase I clinical trial , 2012, BMC Cancer.

[48]  J. Barnholtz-Sloan,et al.  CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011. , 2012, Neuro-oncology.

[49]  Z. Ram,et al.  The impact of enrollment in clinical trials on survival of patients with glioblastoma , 2012, Journal of Clinical Neuroscience.

[50]  S. Phuphanich,et al.  Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients with newly diagnosed glioblastoma , 2012, Cancer Immunology, Immunotherapy.

[51]  R. Sciot,et al.  Stratification according to HGG-IMMUNO RPA model predicts outcome in a large group of patients with relapsed malignant glioma treated by adjuvant postoperative dendritic cell vaccination , 2012, Cancer Immunology and Immunotherapy.

[52]  J. Menten,et al.  Integration of autologous dendritic cell-based immunotherapy in the standard of care treatment for patients with newly diagnosed glioblastoma: results of the HGG-2006 phase I/II trial , 2012, Cancer Immunology, Immunotherapy.

[53]  G. Pond,et al.  Assumptions of expected benefits in randomized phase III trials evaluating systemic treatments for cancer. , 2012, Journal of the National Cancer Institute.

[54]  T. Fojo,et al.  Why do phase III clinical trials in oncology fail so often? , 2012, Journal of the National Cancer Institute.

[55]  L. Liau,et al.  Monitoring of Regulatory T Cell Frequencies and Expression of CTLA-4 on T Cells, before and after DC Vaccination, Can Predict Survival in GBM Patients , 2012, PloS one.

[56]  Karolina Palucka,et al.  Cancer immunotherapy via dendritic cells , 2012, Nature Reviews Cancer.

[57]  Susan M. Chang,et al.  Consensus on the role of human cytomegalovirus in glioblastoma. , 2012, Neuro-oncology.

[58]  D. Schendel,et al.  NOD/scid IL-2Rgnull mice: a preclinical model system to evaluate human dendritic cell-based vaccine strategies in vivo , 2012, Journal of Translational Medicine.

[59]  E. Shaw,et al.  Validation and simplification of the Radiation Therapy Oncology Group recursive partitioning analysis classification for glioblastoma. , 2011, International journal of radiation oncology, biology, physics.

[60]  W. Oyen,et al.  Route of Administration Modulates the Induction of Dendritic Cell Vaccine–Induced Antigen-Specific T Cells in Advanced Melanoma Patients , 2011, Clinical Cancer Research.

[61]  H. Wishart,et al.  Immune Response in Patients With Newly Diagnosed Glioblastoma Multiforme Treated With Intranodal Autologous Tumor Lysate-dendritic Cell Vaccination After Radiation Chemotherapy , 2011, Journal of immunotherapy.

[62]  R. McLendon,et al.  Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma. , 2011, Neuro-oncology.

[63]  J. Engh,et al.  Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {alpha}-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[64]  S. Nelson,et al.  Gene Expression Profile Correlates with T-Cell Infiltration and Relative Survival in Glioblastoma Patients Vaccinated with Dendritic Cell Immunotherapy , 2010, Clinical Cancer Research.

[65]  Raymond Sawaya,et al.  Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[66]  D. Schadendorf,et al.  Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.

[67]  P. Kantoff,et al.  Sipuleucel-T immunotherapy for castration-resistant prostate cancer. , 2010, The New England journal of medicine.

[68]  E. Jaffee,et al.  Cellular Vaccine Approaches , 2010, Cancer journal.

[69]  S. Reed,et al.  Adjuvants for cancer vaccines. , 2010, Seminars in immunology.

[70]  S. Kim-Schulze,et al.  Local and Distant Immunity Induced by Intralesional Vaccination with an Oncolytic Herpes Virus Encoding GM-CSF in Patients with Stage IIIc and IV Melanoma , 2010, Annals of Surgical Oncology.

[71]  Jan Goffin,et al.  Integration of autologous dendritic cell-based immunotherapy in the primary treatment for patients with newly diagnosed glioblastoma multiforme: a pilot study , 2010, Journal of Neuro-Oncology.

[72]  S. Gabriel,et al.  Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. , 2010, Cancer cell.

[73]  P. Keegan,et al.  FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme. , 2009, The oncologist.

[74]  A. Friedman,et al.  An epidermal growth factor receptor variant III–targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme , 2009, Molecular Cancer Therapeutics.

[75]  S. Senju,et al.  An in vivo model of priming of antigen-specific human CTL by Mo-DC in NOD/Shi-scid IL2rgamma(null) (NOG) mice. , 2009, Immunology letters.

[76]  S. Rosenberg,et al.  Ocular and systemic autoimmunity after successful tumor-infiltrating lymphocyte immunotherapy for recurrent, metastatic melanoma. , 2009, Ophthalmology.

[77]  R. Mirimanoff,et al.  Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. , 2009, The Lancet. Oncology.

[78]  K. Black,et al.  Vaccination elicits correlated immune and clinical responses in glioblastoma multiforme patients. , 2008, Cancer research.

[79]  R. Sciot,et al.  Postoperative Adjuvant Dendritic Cell–Based Immunotherapy in Patients with Relapsed Glioblastoma Multiforme , 2008, Clinical Cancer Research.

[80]  S. Hassenbusch,et al.  Immunological responses in a patient with glioblastoma multiforme treated with sequential courses of temozolomide and immunotherapy: case study. , 2008, Neuro-oncology.

[81]  J. Park,et al.  Enhanced antitumour immunity by combined use of temozolomide and TAT‐survivin pulsed dendritic cells in a murine glioma , 2007, Immunology.

[82]  J. Rich,et al.  Cancer stem cells in radiation resistance. , 2007, Cancer research.

[83]  D. Bigner,et al.  Systemic CTLA-4 Blockade Ameliorates Glioma-Induced Changes to the CD4+ T Cell Compartment without Affecting Regulatory T-Cell Function , 2007, Clinical Cancer Research.

[84]  P. Chomez,et al.  A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. , 2007, Journal of immunology.

[85]  Mark W. Dewhirst,et al.  Glioma stem cells promote radioresistance by preferential activation of the DNA damage response , 2006, Nature.

[86]  Qiulian Wu,et al.  Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor. , 2006, Cancer research.

[87]  R. Mirimanoff,et al.  Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[88]  Thomas D. Wu,et al.  Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. , 2006, Cancer cell.

[89]  Simon C Watkins,et al.  Delivery of Dendritic Cells Engineered to Secrete IFN-α into Central Nervous System Tumors Enhances the Efficacy of Peripheral Tumor Cell Vaccines: Dependence on Apoptotic Pathways1 , 2005, The Journal of Immunology.

[90]  Timothy F. Cloughesy,et al.  Dendritic Cell Vaccination in Glioblastoma Patients Induces Systemic and Intracranial T-cell Responses Modulated by the Local Central Nervous System Tumor Microenvironment , 2005, Clinical Cancer Research.

[91]  Naoto Tsuchiya,et al.  Clinical evaluation of dendritic cell vaccination for patients with recurrent glioma: results of a clinical phase I/II trial. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[92]  A. Devillers,et al.  Biodistribution of radiolabelled human dendritic cells injected by various routes , 2005, European Journal of Nuclear Medicine and Molecular Imaging.

[93]  C. Figdor,et al.  Migration of dendritic cell based cancer vaccines: in vivo veritas? , 2005, Current opinion in immunology.

[94]  Martin J. van den Bent,et al.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.

[95]  P. Flamen,et al.  Surgery and adjuvant dendritic cell-based tumour vaccination for patients with relapsed malignant glioma, a feasibility study , 2004, British Journal of Cancer.

[96]  Keith L. Black,et al.  Vaccination with Tumor Lysate-Pulsed Dendritic Cells Elicits Antigen-Specific, Cytotoxic T-Cells in Patients with Malignant Glioma , 2004, Cancer Research.

[97]  E. Bernhard,et al.  Mutant epidermal growth factor receptor displays increased signaling through the phosphatidylinositol-3 kinase/AKT pathway and promotes radioresistance in cells of astrocytic origin , 2004, Oncogene.

[98]  L. Liau,et al.  Immunotherapeutic targeting of shared melanoma-associated antigens in a murine glioma model. , 2003, Cancer research.

[99]  R. Tanaka,et al.  Vaccination of recurrent glioma patients with tumour lysate-pulsed dendritic cells elicits immune responses: results of a clinical phase I/II trial , 2003, British Journal of Cancer.

[100]  S. Rosenberg,et al.  Tumor Regression and Autoimmunity after Reversal of a Functionally Tolerant State of Self-reactive CD8+ T Cells , 2003, The Journal of experimental medicine.

[101]  Thomas A. Davis,et al.  Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[102]  C. Norbury,et al.  Cross priming or direct priming: is that really the question? , 2003, Current opinion in immunology.

[103]  Meredith O'Keeffe,et al.  Human and mouse plasmacytoid dendritic cells. , 2002, Human immunology.

[104]  G. Reichmann,et al.  Brain Dendritic Cells and Macrophages/Microglia in Central Nervous System Inflammation1 , 2001, The Journal of Immunology.

[105]  K. Black,et al.  Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration. , 2001, Cancer research.

[106]  A. Belldegrun,et al.  Treatment of a glioblastoma patient by vaccination with autologous dendritic cells pulsed with allogeneic major histocompatibility complex class I-matched tumor peptides , 2000 .

[107]  Wangxue Chen,et al.  Dendritic cell‐based cancer immunotherapy: Potential for treatment of colorectal cancer? , 2000, Journal of gastroenterology and hepatology.

[108]  G. Reichmann,et al.  Phenotype and Functions of Brain Dendritic Cells Emerging During Chronic Infection of Mice with Toxoplasma gondii1 , 2000, The Journal of Immunology.

[109]  R. McLendon,et al.  Bone marrow-derived dendritic cells pulsed with tumor homogenate induce immunity against syngeneic intracerebral glioma , 2000, Journal of Neuroimmunology.

[110]  W. Oyen,et al.  Biodistribution and vaccine efficiency of murine dendritic cells are dependent on the route of administration. , 1999, Cancer research.

[111]  R. Merchant,et al.  Presentation of the self antigen myelin basic protein by dendritic cells leads to experimental autoimmune encephalomyelitis. , 1999, Journal of immunology.

[112]  W. Heath,et al.  Cytotoxic T lymphocyte activation by cross-priming. , 1999, Current opinion in immunology.

[113]  D. Bigner,et al.  Bone Marrow–generated Dendritic Cells Pulsed with Tumor Extracts or Tumor RNA Induce Antitumor Immunity against Central Nervous System Tumors , 1997, The Journal of experimental medicine.

[114]  D. Bigner,et al.  Receptor dimerization is not a factor in the signalling activity of a transforming variant epidermal growth factor receptor (EGFRvIII). , 1997, The Biochemical journal.

[115]  S. Rosenberg,et al.  Human melanoma antigens recognized by T lymphocytes. , 1996, The Keio journal of medicine.

[116]  E. Gilboa,et al.  Induction of antitumor immunity using bone marrow-generated dendritic cells. , 1996, Journal of immunology.

[117]  L. Zitvogel,et al.  Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines , 1996, The Journal of experimental medicine.

[118]  L. Zitvogel,et al.  Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity , 1995, Nature Medicine.

[119]  E. Gilboa,et al.  Bone marrow-generated dendritic cells pulsed with a class I-restricted peptide are potent inducers of cytotoxic T lymphocytes , 1995, The Journal of experimental medicine.

[120]  E. Jaffee,et al.  Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. , 1994, Science.

[121]  M. Moser,et al.  Murine dendritic cells pulsed in vitro with tumor antigen induce tumor resistance in vivo , 1994, European journal of immunology.

[122]  S. Rosenberg,et al.  Murine epidermal Langerhans cells and splenic dendritic cells present tumor‐associated antigens to primed T cells , 1994, European journal of immunology.

[123]  M. Lotze,et al.  Identification of T-cell epitopes: rapid isolation of class I-presented peptides from viable cells by mild acid elution. , 1993, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.

[124]  P. Chomez,et al.  A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. , 1991, Science.

[125]  P. Humphrey,et al.  Anti-synthetic peptide antibody reacting at the fusion junction of deletion-mutant epidermal growth factor receptors in human glioblastoma. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[126]  H. Fujiwara,et al.  Induction of tumor-specific in vivo protective immunity by immunization with tumor antigen-pulsed antigen-presenting cells. , 1989, Journal of immunology.

[127]  P. Chomez,et al.  Immunogenic (tum-) variants of mouse tumor P815: cloning of the gene of tum- antigen P91A and identification of the tum- mutation. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[128]  K. Kinzler,et al.  Increased expression of the epidermal growth factor receptor gene in malignant gliomas is invariably associated with gene amplification. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[129]  D. Bigner,et al.  Induction of lethal experimental allergic encephalomyelitis in nonhuman primates and guinea pigs with human glioblastoma multiforme tissue. , 1981, Journal of neurosurgery.

[130]  R. Steinman,et al.  Dendritic Cells: Features and Functions , 1980, Immunological reviews.

[131]  P. Medawar.  Immunity to homologous grafted skin; the fate of skin homografts transplanted to the brain, to subcutaneous tissue, and to the anterior chamber of the eye. , 1948, British journal of experimental pathology.

[132]  W. Coley,et al.  THE TREATMENT OF MALIGNAT TUMORS BY REPEATED INOCULATIONS OF ERYSIPELAS: WITH A REPORT OF TEN ORIGINAL CASES , 1893 .

[133]  R. Schreiber,et al.  The Role of Neoantigens in Naturally Occurring and Therapeutically Induced Immune Responses to Cancer. , 2016, Advances in immunology.

[134]  J. Barnholtz-Sloan,et al.  Years of potential life lost for brain and CNS tumors relative to other cancers in adults in the United States, 2010. , 2016, Neuro-oncology.

[135]  I. Hermans,et al.  Dendritic cell vaccination combined with temozolomide retreatment: results of a phase I trial in patients with recurrent glioblastoma multiforme , 2014, Journal of Neuro-Oncology.

[136]  J. Barnholtz-Sloan,et al.  CBTRUS statistical report: Primary brain and central nervous system tumors diagnosed in the United States in 2006-2010. , 2013, Neuro-oncology.

[137]  X. Ju,et al.  Review of human DC subtypes. , 2010, Methods in molecular biology.

[138]  Antonio Lanzavecchia,et al.  Dendritic cell migration to peripheral lymph nodes. , 2009, Handbook of experimental pharmacology.

[139]  R. Steinman,et al.  Pillars Article: Identification of a novel cell type in peripheral lymphoid organs of mice. I. Morphology, quantitation, tissue distribution. J. Exp. Med.1973. 137: 1142-1162. , 2007, Journal of immunology.

[140]  E. Imyanitov,et al.  Cell technologies in immunotherapy of cancer. , 2007, Advances in experimental medicine and biology.

[141]  D. Bigner,et al.  The History, Evolution, and Clinical use of Dendritic Cell-Based Immunization Strategies in the Therapy of Brain Tumors , 2004, Journal of Neuro-Oncology.

[142]  Laurence Zitvogel,et al.  Antigen presentation and T cell stimulation by dendritic cells. , 2002, Annual review of immunology.

[143]  A. Maroof.  Generation of murine bone-marrow-derived dendritic cells. , 2001, Methods in molecular medicine.

[144]  B. Czerniecki,et al.  Diverse functional activity of CD83+ monocyte-derived dendritic cells and the implications for cancer vaccines. , 2001, Critical reviews in immunology.

[145]  A. Belldegrun,et al.  Treatment of a patient by vaccination with autologous dendritic cells pulsed with allogeneic major histocompatibility complex class I-matched tumor peptides. Case Report. , 2000, Neurosurgical focus.

[146]  W. Coley.  The Classic: The Treatment of Malignant Tumors by Repeated Inoculations of Erysipelas , 1991 .